ArticleAnnals of hematology2017
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
Article in Annals of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis.JAMA dermatology · 2019Pooled it
- Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis.ACR open rheumatology · 2026Article
- MAGa: Monoclonal Autoimmune Gammopathies.Cancers · 2026Review
- Survival in patients with monoclonal gammopathy of unknown significance after transcatheter aortic valve replacement: a global retrospective propensity-matched real-world analysis.Cardio-oncology (London, England) · 2026Article
- Immunoglobulin G4 Smoldering Multiple Myeloma With Immunoglobulin G4-Related Autoimmune Hepatitis: A Rare Case Report.Immunity, inflammation and disease · 2025Article
- Association of ANA and SSA autoantibodies with progression-free survival in multiple myeloma: a retrospective cohort study.Frontiers in oncology · 2025Article
- Article
- Regarding the prognostic role of vitamin D deficiency in a Japanese multiple myeloma study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Association between Multiple Myeloma and Ulcerative Colitis: A Cross-Sectional Analysis.Diseases (Basel, Switzerland) · 2023Article
- Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.International journal of molecular sciences · 2023Article
- Synchronous Presentation of Autoimmune Hepatitis and Multiple Myeloma.Journal of hematology · 2022Article
- Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.Clinical case reports · 2022Article
- Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.Blood advances · 2021Article
- Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.European journal of haematology · 2021Article
- Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020Review
- Association of Multiple Myeloma and Giant Cell Arteritis - A Case Report.European journal of case reports in internal medicine · 2020Article
- [Monoclonal gammopathy of undetermined significance and multiple myeloma].Zeitschrift fur Rheumatologie · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a plasma cell disorder preceded by monoclonal gammopathy of undetermined significance (MGUS). Incidence of MM and MGUS is higher among patients with autoimmune disease. The aim of this study was to determine whether a history of autoimmunity has an impact on survival in MM and MGUS. Using high-quality national Swedish registries, we identified 8367 patients with MM, 18,768 patients with MGUS, and 110,251 matched control subjects, and obtained information on previous autoimmune disease in patients and controls. Cox regression was used to calculate hazard ratios (HRs) for overall survival with 95 % confidence intervals (CIs). In patients with MM and a prior autoimmune disease, the risk of death was significantly increased, HR = 1.2 (95 % CI 1.2-1.3) compared to MM patients with no history of autoimmunity. In MGUS patients, a prior autoimmune disease was associated with a significantly 1.4-fold elevated risk of death (95 % CI 1.3-1.4). When analyzing different types of autoimmune diseases, a history of ulcerative colitis had a stronger impact on survival in MM than in controls. Our findings that a history of autoimmune disease has a negative impact on survival in MM and MGUS could be due to shared underlying common genetic factors, or that patients with a history of autoimmunity develop more severe cases of MM and MGUS, or cumulative comorbidity in the individual. Our results suggest that more attention should be paid to comorbidity as a prognostic factor in MGUS and MM, and underlines the need for studies aimed at tailoring therapy according to comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.